Our objective is to elucidate the usefulness of maspin/ p53 double immunostaining on biliary brushing cytology specimens. We first examined the expression of maspin in the biliary epithelium with variable degrees of dysplasia using surgically resected specimens (n ¼ 56). Maspin appeared to be overexpressed in a stepwise manner from benign to malignant cholangiocytes: the reactive epithelium (20%), biliary intraepithelial neoplasia ($50%), and invasive cholangiocarcinomas (>90%). Next, an automated sequential double immunostaining protocol for maspin and p53 was applied to paraffin-embedded cell blocks of the biliary brushing cytology specimens obtained from 58 consecutive patients. Cell block preparation was successful in 44 cases (76%), which were morphologically diagnosed as adenocarcinoma (n ¼ 16), atypical cells not diagnostic for malignancy (n ¼ 10), and benign (n ¼ 18). Double positive cells were observed in 14/16 (88%) morphologically malignant, 6/10 (60%) borderline, and 0/18 benign cases. All 20 positive cases were proven to have pancreatobiliary malignancies by subsequent imaging or pathological analyses. A similar staining protocol for S100P and p53 was also applied to the same cohort; however, the positive frequency was slightly lower than those of maspin and p53 (36% vs. 45%). In conclusion, Maspin/p53 double immunostaining on cell blocks contributes to the detection of malignant cells in biliary brushing cytology specimens.
Biliary cytology is one of main procedures that enable us to establish a diagnosis of malignancy before surgery. 1 Bile duct brushing generally provides more preserved cells than bile cytology. However, mucosal brushing specimens are still difficult to interpret because they are often paucicellular and background inflammatory changes may lead to severe secondary changes in cholangiocytes (e.g., nuclear enlargement). The diagnostic rate of definite malignancy by biliary brushing cytology is estimated to be up to 40%. 2, 3 Therefore, ancillary methods to improve the diagnostic value of biliary cytology specimens are awaited. Immunohistochemistry, fluorescent in situ hybridization, and gene mutation analyses have been examined in this aspect; however, none have been widely used in clinical practice. [3] [4] [5] [6] [7] [8] The use of automated immunostainers became more widespread in the last decade, and, as a consequence, double-epitope immunostaining is now markedly easier to perform and frequently used in daily practice (e.g., cocktail antibodies "PIN4" for prostate cancers). 9, 10 Double immunostaining may increase diagnostic specificity. One example is that although a single malignant marker (e.g., p53) sometimes leads to a false positive result, cells simultaneously positive for two cancer-related molecules are supposedly more specific for a diagnosis of malignancy.
In the present study, three molecules that are known to be strongly expressed in cholangiocarcinomas were examined. Similar to many other malignant neoplasms, approximately 80% of cholangiocarcinomas are immunoreactive to p53, while only up to 10% of biliary intraepithelial neoplasia (BilIN) or almost no nonneoplastic cholangiocytes are p53-positive.
11 S100P is another protein that is aberrantly expressed in malignant cholangiocytes. 8, 12 S100P is involved in the regulation of cell migration and proliferation through an interaction with ezrin. 13, 14 This calcium-binding protein belonging to the S100 protein family is typically negative in the non-neoplastic biliary epithelium, but is overexpressed in an almost stepwise manner during biliary carcinogenesis: BilIN1 (45%), BilIN2 (67%), BilIN3 (100%), and cholangiocarcinoma (63%).
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The last protein examined is maspin (a mammary serine protease inhibitor), which was originally identified as a potential tumor suppressor gene for breast cancers. 15 Subsequent studies confirmed that the expression of maspin was lost or significantly down-regulated in prostatic and colonic cancers, while it was overexpressed in pancreatic cancers. [16] [17] [18] [19] [20] Although its functions have not yet been fully clarified, its potential roles in cell growth and invasion as well as the metastatic properties of cancer cells have been suggested. 21 Previous studies demonstrated that maspin is upregulated in cholangiocarcinomas. [22] [23] [24] [25] Up to 88% of cholangiocarcinomas were found to be immunoreactive to maspin. 22 However, its specificity remains unclear because maspin expression in BilIN and non-neoplastic biliary epithelium has not been systematically examined until now. The present study aimed to investigate the usefulness of double immunostaining on biliary brushing cytology specimens. Tissue and cytology examinations were performed. We first examined the expression of maspin in cholangiocarcinomas, BilINs, and regenerative biliary epithelia using surgically resected specimens in order to elucidate the specificity of maspin expression in cholangiocarcinomas. We then applied a double immunostaining protocol to biliary brushing cytology samples.
MATERIALS AND METHODS

Surgical specimens
The study was approved by the Institutional Review Boards at the authors' institutions. The first part of the study consisted of 56 surgically resected cases. Forty-two patients had hepatolithiasis with an inflammatory regenerative epithelium (n ¼ 9), BilIN1 (n ¼ 10), BilIN2 (n ¼ 10), BilIN3 (n ¼ 6), or invasive intrahepatic large-duct cholangiocarcinomas (n ¼ 7). The remaining patients had de novo hilar/extrahepatic cholangiocarcinomas (n ¼ 14). The average age and sex of patients were as follows: regenerative epithelium, mean age 50 (range 42-60), M: 
Single immunostaining for maspin in surgical specimens
All samples were fixed in 10% buffered formalin and embedded in paraffin. One representative block was selected for immunohistochemistry from each case. Immunostaining was performed on a Bond-Max autostainer (Leica Microsystems, Wetzlar, Germany) according to the manufacturers' protocols. Deparaffinized sections were heat-treated and incubated with a primary antibody against maspin (a mouse monoclonal antibody, clone EAW24, dilution 1:75, Leica Microsystems).
Expression levels were evaluated semiquantitatively according to the percentage of positive cells: 0 (negative); 1þ (focal), 1-5%; 2þ (moderate), 6-50%; and 3þ (diffuse), more than 50%. Moderate or marked expression (2þ or 3þ) was considered to be positive.
Handling of cytology specimens
The second part of study consisted of 58 bile duct brushing cytology specimens consecutively obtained at Kitaharima Medical Center between July 2014 and February 2016. After two smear slides for Papanicolaou staining had been prepared, the brush was immersed into RPMI-1640 medium (Sigma-Aldrich, St. Louis, MO, USA). After centrifuging at 3000 rpm for 3 min, the cell pellets obtained were fixed in 10% buffered formalin. Cell blocks were made by embedding the cells with 1% sodium alginate (Wako Pure Chemical Industries, Osaka, Japan) in a 1 M calcium chloride solution, and were processed similar to ordinary tissue samples. Among the three slices cut from each cell block, one was stained with hematoxylin and eosin, while the other two were used for double immunostaining.
Cytological diagnoses were made based on purely morphological grounds from Papanicolaou-stained slides. In our practice, biliary brushing cytology samples are classified into four categories: "malignant"; "suspected malignancy"; "atypical cells present, but not diagnostic for malignancy (an indeterminate category)"; and "benign". In the present study, they were re-classified into three by combining the first two groups as "adenocarcinoma". Morphological diagnoses and the results of double immunostaining were correlated.
Double immunostaining
Double staining was made for the combination of maspin/p53 or S100P/p53 because maspin and S100P are mainly expressed in the cytoplasm with occasional Microsystems) for 20 min, slides were sequentially incubated with the first primary antibody for p53 (clone DO-7, dilution 1:400, Leica Microsystems) and the second primary antibodies for either maspin (Leica Microsystems) or S100P (clone 357517, dilution 1:500, R&D systems, Minneapolis, USA). In this protocol, p53 was stained with 3,3'-diaminobenzidine (DAB) in brown, while maspin and S100P were visualized with alkaline phosphatase in red.
The cytoplasmic staining of maspin and S100P and nuclear staining of p53 were evaluated. Cases with at least one glandular cell convincingly positive for both markers were qualified as a positive result. Cells expressing a single marker were separately recorded.
Statistical analysis
Statistical analyses were performed using the chi-square or Fisher's exact test. A probability of P < 0.05 was considered significant.
RESULTS
Maspin expression in surgical specimens
The results of immunohistochemistry are shown in Fig. 1 . Maspin was moderately expressed in the regenerative biliary epithelia of 2/9 (22%) cases. Its expression appeared to increase in a stepwise manner from BilIN to cholangiocarcinomas. Approximately 50% of BilIN2/3 were diffusely positive for maspin. The moderate to extensive expression of maspin was also observed in 20/21 (95%) cases of cholangiocarcinomas. These results suggest that the expression of maspin is highly sensitive and moderately specific for a dysplastic or malignant biliary epithelium.
Clinical features and classification of cytology cases
During the study period, 58 patients underwent biliary brushing cytology examinations. All patients presented with biliary obstruction/stenosis with or without mass lesions. The preparation of cell blocks containing >50 glandular cells per section was successful in 44 cases (76%), but failed in the remaining cases because of pauci-cellular samples. No significant difference was observed between successful and non-successful cases in terms of the location of the biliary stricture. The 44 cases with cell blocks available were hereafter examined with additional immunohistochemistry. Based on the morphological appearance on Papanicolaoustained slides, cases were cyto-morphologically diagnosed as adenocarcinoma (n ¼ 16), atypical cells not diagnostic for malignancy (n ¼ 10), and benign (n ¼ 18). Ages, genders, and the lesional locations of cases categorized into individual groups were summarized in Table 1 .
Double immunostaining
In all cases that contained atypical cells in Papanicolaoustained slides, similar atypical cells were also present on Figure 3 S100P/p53 double staining in cell blocks of biliary brushing specimens. Double positive cells are observed in cases that are morphologically diagnosed as borderline or malignancy, while the benign case is entirely negative. Papanicolaou, smear slides; H&E and S100P/p53, cell block specimens. cell block slides. Double positive cells were easily identified in maspin/p53 and S100P/p53 stains. Red signals for maspin and S100P were mainly observed in the cytoplasm, while the dark brown staining of p53 was noted in nuclei. Glandular cells double positive for maspin and p53 were detected in 14/16 (88%) cases of morphologically adenocarcinoma and 6/10 (60%) borderline cases (Fig. 2 , Table 2 ). None of the cases that were morphologically classified as negative contained double positive cells (Fig. 2) . Similarly, S100P/p53 double positive cells were present in 10/16 (63%) cases of adenocarcinoma, 6/10 (60%) borderline lesions, and none of the morphologically benign cases (Fig.  3 , Table 2 ). Double positive cells were also found in cases that contained only a small number of atypical cells (Fig. 4) . Some cases in the benign group were positive for single markers. Specifically, 8 (44%) cases were positive for only maspin, and 2 (11%) were positive for p53, but negative for maspin ( Table 2) . Comparisons of the results between the two staining protocols revealed that the positive frequency of maspin/ p53 was slightly higher than that of S100P/p53 (P ¼ 0.091). In borderline lesions, one case each was positive for either maspin/p53 or S100P/p53 alone, while four cases were positive for both types of double staining.
Clinical outcomes
All morphologically malignant or borderline cases (n ¼ 26) were proven to have pancreatic or biliary cancers based on an additional tissue biopsy (n ¼ 7), progressive imaging features such as the development of liver metastasis (n ¼ 10), and tissue examinations of surgically resected specimens (n ¼ 9).
Malignancy was also confirmed in 6/18 morphologically negative cases based on the clinical course and subsequent tissue diagnosis. However, no atypical cells were identified, even in a retrospective review, suggesting that lesional cells were missed in original specimens. The remaining negative cases were eventually diagnosed as primary sclerosing cholangitis (n ¼ 1), autoimmune pancreatitis/IgG4-related sclerosing cholangitis (n ¼ 2), chronic pancreatitis (n ¼ 2), post-surgery biliary stenosis (n ¼ 2), choledocholithiasis (n ¼ 4), and benign biliary stricture of an unknown nature (n ¼ 1). No evidence of malignancy has been identified until now in the 10 cases positive for a single marker (either maspin or p53) in the benign group. Table 3 compares diagnostic values of single and double immunostaining. For making this analysis, patients that showed atypical cells on cytology samples and were also proven to have malignant clinical course and/or subsequent tissue diagnosis (n ¼ 26) were considered as malignant cases. Diagnostic sensitivity of maspin/p53 and S100P/p53 double immunostaining was not particularly higher than single immunostaining. However, double staining protocol yielded nearly 100% specificity and positive predictive value (Table 3 ). Maspin single immunostaining had high sensitivity (89%), but low specificity (56%). Figure 4 Maspin/p53 double staining in a case of a paucicellular sample. This case was morphologically diagnosed as atypical cells not diagnostic for malignancy; however, some cells appear to be double positive for maspin and p53. Papanicolaou, smear slide; maspin/p53, cell block specimen. 
DISCUSSION
The results obtained in the present study are summarized as follows: (i) Similar to S100P and p53, maspin is commonly expressed in cholangiocarcinomas, suggesting that its expression in the biliary epithelium serves as a highly sensitive and moderately specific immunohistochemical marker for reaching diagnoses.
(ii) Double immunostaining for maspin/p53 or S100P/p53 is useful for detecting malignant cells in cytology specimens, and suggested malignancy in 60% of morphologically borderline cases. (iii) Both maspin/p53 and S100P/p53 staining protocols seem to be similarly useful. Given that the former showed higher sensitivity and negative predictive value than the latter, the combination of maspin/p53 may be slightly superior to that of S100P/p53 for identifying malignant cells in brushing samples. (iv) All cases that contained atypical cells double positive for maspin/p53 or S100P/p53 were proven to have pancreatobiliary carcinomas in follow-ups. The preoperative diagnosis of bile duct malignancy remains challenging but crucial because 5-10% of histology-unproven mass lesions are subsequently identified as benign processes after surgery. 26, 27 Biliary brushing cytology, bile duct biopsy, and bile cytology are the main procedures used for preoperative diagnoses. 28, 29 Of these, biliary brushing cytology is supposedly the most widely used technique. In our cohort, a diagnosis of malignancy was reached in 36% of cases based on purely morphological grounds similar to previous studies, 2,3 while an additional 14% were suspected of malignancy by maspin/p53 staining with nearly 100% specificity. The diagnostic "borderline" category is problematic in clinical practice, and this group is still large in biliary brushing cytology. The double immunostaining protocol will be useful, particularly for this group, and may allow us to transfer approximately 60% of morphologically borderline cases from the indeterminate group to malignant category. Two previous studies examined the expression of maspin in bile duct biopsy samples. In the study conducted by Chen et al., in which 134 endoscopic bile duct biopsy specimens were analyzed, diffuse and strong/intermediate staining was observed in 40% of malignant cases and 12% of benign samples. 25 The expression of maspin was also noted in 43% (12/31 cases) of atypical cases in which a diagnosis of adenocarcinoma or reactive atypia was not definitively reached. During follow-ups, eight out of 12 maspin-positive borderline cases were subsequently diagnosed with adenocarcinoma, while the other four cases remained benign, suggesting that the expression of maspin in biopsy samples is not entirely specific for adenocarcinoma. Thus, the authors proposed that the combination of maspin, S100P, and the von Hippel-Lindau gene product (pVHL) is more useful for diagnoses than single markers because the immunophenotype maspinþ/S100Pþ/pVHLwas almost 100% specific for malignancy. 25 Keira et al. also reported a similar finding showing that the combined use of maspin with other malignant markers such as claudin 18 or p53 achieved a more reliable distinction between benign and malignant cholangiocytes in bile duct biopsy specimens than maspin alone. 24 The results of the present study are consistent with the conclusions of the two previous studies. 24, 25 Cells positive for either maspin or p53 alone were detected in 8 (44%) and 2 (11%) cases of the benign category, respectively. However, even in retrospect, no atypical cells were found in these cytology samples. In addition, no evidence of malignancy has been identified until now in any of these patients, suggesting that maspin can be expressed in benign cholangiocytes. In contrast, although S100P was negative in all benign cases, its expression was less frequent in the malignant group than maspin and p53. Therefore, combinations of multiple markers are currently necessary in order to increase the diagnostic specificity of cytology specimens without losing sensitivity. A beneficial aspect of double immunostaining in cytology samples is that the diagnostic specificity can be increased up to nearly 100%. Prior to the initiation of the present study, several preliminary studies were conducted in order to optimize the staining procedure. The first question to be clarified was whether cell block or smear samples are more useful for double immunostaining. Double staining on smear samples was technically feasible, but double positive cells were difficult to identify. Although positive signals were observed among sterically fixed cell nests, it was challenging to conclude which cells were expressing the molecule. Thus, cell blocks appeared to be superior to smear samples in this aspect. The next issue to be resolved was which markers need to be stained in red or brown. Staining maspin/S100P in red and p53 in brown was superior to the opposite condition. When maspin/S100P was colored in brown, nuclei were occasionally stained brown (maspin and S100P are frequently expressed in nuclei as well as the cytoplasm), which significantly masked the red signal derived from p53.
A limitation of this study is that the preparation of cell block samples was only successful in 76% of cases (44/58 cases). Familiarity with the preparation procedure may be one reason for this. In the first half of the 19-month study period, cell blocks were successfully made in 63% (19/30 cases), but in 89% (25/28 cases) in the remaining period. Thus, if the proposed protocol is routinely used, the successful rate of sample preparation will become higher.
In conclusion, maspin/p53 double immunostaining on cell blocks of biliary brushing cytology samples increases diagnostic sensitivity without losing specificity. This approach will be particularly useful for borderline cases, in which a diagnosis of adenocarcinoma or reactive atypia cannot be definitively made on morphological findings alone.
